Dr Reddy S Laboratories Limited (RDY) Return on Investment ROI from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Dr Reddy s Laboratories Limited  (NYSE: RDY)


Dr Reddy S Laboratories Limited's ROI from its fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Dr Reddy S Laboratories Limited's ROI in the fourth quarter of 2026?
Dr Reddy s Laboratories Limited achieved a return on average invested assets (ROI) of 10.39 % in its fourth quarter of 2026, which is below Dr Reddy S Laboratories Limited's average return on investment, which stands at 12.73%.

ROI fell compared to the third quarter of 2026, despite the net income growth of % from the third quarter of 2026.

Within the Healthcare sector 107 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2026 from 0 to 801.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Mar 31 2025)
IV. Quarter
Y / Y Investment Change TTM 7.24 % 11.49 % 11.16 % 16.03 % 21.45 %
Y / Y Net Income Change TTM -32.64 % 0.45 % 0.45 % 0.45 % 0.45 %
Investment (TTM) in Millions 4,388 4,245 4,388 4,388 4,245
Return On Investment (TTM) 10.39 % 15.55 % 16.25 % 16.39 % 16.53 %
RDY's Overall Ranking # 801 # 0 # # #
Seq. Investment Change TTM 0.83 % 4.52 % 0.87 % 0.88 % 4.82 %
Seq. Net Income Change TTM -32.64 % 0 % 0 % 0 % 0.45 %
Net Income (TTM) in Millions 452 671 671 671 671

RDY Company Profile >> Back to RDY Roi Comparisons >> See Annual RDY Return On Investment



Return On Investment RDY's Ranking
Within: No.
Industry # 43
Sector # 108
Overall # 801

Return On Investment Statistics
High Average Low
19.1 %
12.73 %
4.36 %
(Mar 31 2024)   (Mar 31 2018)







Financial Statements
Dr Reddy S Laboratories Limited's IV. Quarter Investments $ 4,388 Millions RDY's Balance sheet
Dr Reddy S Laboratories Limited's IV. Quarter Income $ 452 Millions Quarterly RDY's Income Statement
RDY's Income by Division See RDY's Income by Division


RDY Annual Return On Investment (Mar 31 2026)
2026		 (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Mar 31 2023)
2023		 (Mar 31 2022)
2022
Total Investments in Millions 4,388 4,245 3,498 2,872 2,620
Y / Y Investment Growth 3.37 % 21.36 % 21.8 % 9.62 % 5.22 %
Net Income in Millions 452 671 668 548 311
Y / Y Net Income Growth -32.64 % 0.45 % 21.9 % 76.21 % 31.78 %
Annual Return On Investment 10.3 % 15.81 % 19.1 % 19.08 % 11.87 %


Annual Roi Comment
In the fiscal year 2026 ROI decreased relative to the previous year to 10.3 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RDY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RDY's Competitors
Subscribers only: Roi for Dr Reddy S Laboratories Limited's Suppliers
Subscribers only: Return On Investment for RDY's Customers

Other Ratios
RDY's Roa RDY's Inventory Turnover Ratio RDY's Growth Rates RDY's Dividend Statistics
RDY's Profitability Ratios RDY's Asset Turnover Ratio RDY's Dividend Growth
RDY's Roe RDY's Valuation Ratios RDY's Financial Strength Ratios RDY's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Rafael Holdings Inc  28.08 %
Incyte Corporation  27.50 %
Carlisle Companies Incorporated  24.39 %
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %
Dexcom Inc   22.17 %
Illumina Inc   22.01 %
Pro dex Inc   20.88 %
Gilead Sciences Inc   20.52 %
Vertex Pharmaceuticals Inc  20.49 %
Agilent Technologies inc   20.46 %
Zoetis Inc   20.35 %
Resmed Inc   20.23 %
Soleno Therapeutics Inc  19.51 %
Krystal Biotech Inc   19.07 %
Puma Biotechnology Inc   18.83 %
United Therapeutics Corporation  18.64 %
Hca Healthcare Inc   18.54 %
Chemed Corporation  18.36 %
Apellis Pharmaceuticals Inc   17.94 %
Neurocrine Biosciences Inc   17.65 %
Halozyme Therapeutics Inc   17.53 %
Transmedics Group Inc   17.09 %
Inspire Medical Systems inc   16.60 %
Aveanna Healthcare Holdings Inc   16.38 %
Intuitive Surgical Inc   16.36 %
Alnylam Pharmaceuticals Inc   16.15 %

Date modified: 2026-07-07T13:23:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.